Company intelligence / Profile preview

Ichor Biologics

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Ichor Biologics has demonstrated pre-clinical efficacy of its lead antibody-based drugs against lethal hantavirus infections in animal models and received NIH funding to advance development. Published data indicates protection of animals against hantavirus in collaboration with external academic and government partners[3][4].

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Drug pipeline

1 asset

immuglo

Unknown

Partnerships

National Institutes of HealthUniversity of Concepción

Beyond the preview

Go deeper on Ichor Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ichor Biologics.

Explore the full profile